The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Potential predictive markers of chemotherapy for advanced gastric cancer: Biomarker study in GC0301/TOP-002, randomized phase III study of irinotecan plus S-1 versus S-1.
Naotoshi Sugimoto
No relevant relationships to disclose
Akira Tsuburaya
No relevant relationships to disclose
Ryohei Kawabata
No relevant relationships to disclose
Kazuhiro Nishikawa
No relevant relationships to disclose
Haruhiko Imamoto
No relevant relationships to disclose
Toshimasa Tsujinaka
No relevant relationships to disclose
Taito Esaki
No relevant relationships to disclose
Yosuke Horita
No relevant relationships to disclose
Yutaka Kimura
No relevant relationships to disclose
Tsuneaki Fujiya
No relevant relationships to disclose
Osamu Takayama
No relevant relationships to disclose
Ryo Oono
No relevant relationships to disclose
Hiroshi Yabusaki
No relevant relationships to disclose
Masataka Taguri
No relevant relationships to disclose
Satoshi Morita
No relevant relationships to disclose
Wasaburo Koizumi
No relevant relationships to disclose
Patrick Tan
No relevant relationships to disclose
Motoki Ninomiya
No relevant relationships to disclose
Hiroshi Furukawa
No relevant relationships to disclose
Mitsuru Sasako
No relevant relationships to disclose